Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
BenchChem	⤷ Start Trial	B1248494	⤷ Start Trial
THE BioTek	⤷ Start Trial	bt-1581301	⤷ Start Trial
Starshine Chemical	⤷ Start Trial	2023-05-9C01371	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 29, 2025

Introduction

Fluoroestradiol F-18 (FES) is a radiopharmaceutical agent primarily used in positron emission tomography (PET) imaging to evaluate estrogen receptor-positive breast cancers and other estrogen-related pathologies. Its efficacy relies on high-purity, reliably sourced Active Pharmaceutical Ingredient (API). As the demand for precision diagnostics and personalized medicine rises, securing consistent, high-quality bulk API sources becomes indispensable for pharmaceutical companies, imaging centers, and research institutions.

This comprehensive overview outlines the key sources, manufacturing processes, regulatory considerations, and market dynamics associated with bulk Fluoroestradiol F-18 API procurement.

Understanding Fluoroestradiol F-18 API

Fluoroestradiol F-18 is a fluorine-18 labeled derivative of estradiol. Its synthesis involves complex radiochemistry, typically starting from precursor molecules that undergo nucleophilic substitution with fluorine-18 (produced via cyclotrons). The resulting molecule must meet stringent purity and sterility standards suitable for human injection.

Key attributes of this API include:

Radioactive Composition: Fluorine-18 (half-life ~110 minutes).
Chemical Purity: High (>95%) to ensure imaging accuracy.
Radionuclidic Purity: Free from other radioactive impurities.
Sterility & Aseptic Conditions: Mandatory for clinical use.

Primary Sources of Bulk Fluoroestradiol F-18 API

1. Established Radiopharmaceutical Manufacturers

Leading pharmaceutical firms specializing in radiochemistry and PET tracers are the most significant sources of bulk Fluoroestradiol F-18 API. Their capabilities encompass cyclotron irradiation, sophisticated radiochemical synthesis, and strict quality assurance.

a. Eczacıbaşı-Monrol Nuclear Products (Turkey)
Eczacıbaşı-Monrol has extensive experience producing F-18 labeled compounds for PET imaging. Their facilities are accredited to produce clinical-grade F-18 APIs, including derivatives like FES.

b. ABX-CRO GmbH (Germany)
ABX-CRO offers custom radiochemistry services, including bulk F-18 labeled radiotracers. Their advanced cyclotron facilities and GMP compliance position them as reliable API sources.

c. IBA Molecular (Belgium/USA)
A prominent player in radiopharmaceuticals, IBA Molecular produces F-18 isotopes and radiotracers, with capabilities for custom API synthesis, including FES.

d. Nordion (Canada)
Known for their cyclotron-produced isotopes, Nordion may facilitate the production of precursors or the F-18 labeled API directly, especially for large-scale clinical use.

2. Contract Manufacturing Organizations (CMOs)

Certain CMOs specialize in radiopharmaceutical synthesis, offering scalable API production tailored to pharmaceutical companies’ needs.

a. Jubilant Radiopharma (USA)
Jubilant offers radiopharmaceutical manufacturing and analytical testing services. They have developed F-18 based tracers, including FES, for clinical use.

b. Jubilant Radiopharmaceuticals (India)
Expanding globally, Jubilant provides radiochemical synthesis services, with capabilities relevant to F-18 API bulk production.

c. Sumitomo Heavy Industries (Japan)
They operate cyclotrons and provide radiochemistry services, including F-18 synthesis, catering to clinical and research markets.

3. Research Institutions and University Facilities

Some academic centers possess cyclotron capabilities and conduct small-scale production of F-18 labeled compounds, including FES, often for research purposes but occasionally for clinical validation.

Limitations:

Generally not GMP-certified.
Limited production scale.
Variable quality assurance procedures.

However, partnerships with commercial GMP facilities can leverage academic expertise.

Manufacturing and Quality Assurance

The production of F-18 labeled API involves multiple critical steps:

Cyclotron Production of Fluorine-18:
Proton irradiation of enriched oxygen-18 water generates F-18.
Radiochemical Synthesis:
Nucleophilic substitution reactions with appropriate precursors (like estradiol derivatives) are performed within shielded hot cells under GMP conditions.
Purification & Sterilization:
Purification processes include HPLC, ensuring chemical and radiochemical purity. Sterilization procedures adhere to pharmaceutical standards.
Quality Control:
Comprehensive testing ensures compliance with pharmacopeial standards, including radiochemical purity (>95%), sterility, endotoxins, and residual solvents.

Regulatory Landscape

Suppliers of bulk F-18 API must adhere to Good Manufacturing Practices (GMP) and obtain approvals from regulatory agencies such as the FDA (USA), EMA (Europe), or respective authorities in their jurisdiction. Exporters should provide Certificates of Analysis (CoA), sterility reports, and radionuclidic purity certifications.

Given the short half-life of F-18, distribution logistics are critical. Most suppliers produce on-demand or within a tight time window in proximity to clinical sites.

Market Dynamics and Challenges

Limited Production Facilities:
The specialized nature of F-18 API synthesis restricts the number of manufacturers, creating supply constraints, especially during high-demand periods.
Regulatory Hurdles:
Variations in regulatory standards can complicate cross-border distribution of radiopharmaceutical APIs.
Short Half-Life:
The 110-minute half-life demands rapid transportation and immediate use, limiting the geographic reach of suppliers.
Customization and Scale:
Manufacturers often provide tailored synthesis routes for specific institutional needs, and production scale can influence pricing and availability.

Emerging Trends

Automation and On-Site Production:
Increasing adoption of compact cyclotrons and automated synthesis modules enables hospitals and research centers to produce F-18 FES in-house, decreasing dependency on external bulk API sources.
Regulatory Harmonization:
Efforts toward international standards streamline cross-border procurement, encouraging broader supplier participation.
Innovative Labeling Techniques:
Novel radiochemistry approaches aim to improve yield, purity, and stability of F-18 labeled estradiol derivatives, enhancing API quality.

Conclusion

Securing bulk API sources for Fluoroestradiol F-18 remains a specialized domain dominated by few experienced manufacturers equipped with advanced cyclotron and radiochemistry facilities. Leading providers like Eczacıbaşı-Monrol, ABX-CRO, IBA Molecular, and Jubilant Radiopharma represent the primary sources capable of delivering GMP-grade, high-purity F-18 API essential for clinical imaging.

For businesses aiming to procure FES API, establishing partnerships with these manufacturers or investing in in-house cyclotron and radiochemistry capabilities constitutes a strategic approach. Given the evolving regulatory landscape and technological advancements, stakeholders should prioritize quality, compliance, and logistical efficiency.

Key Takeaways

Major Suppliers: Predominantly specialized radiopharmaceutical companies with GMP-certified facilities; few global entities dominate the F-18 FES API supply chain.
Regulatory Compliance: Stringent standards and certifications are mandatory for clinical use, influencing supplier selection.
Logistics & Half-Life: F-18’s short half-life necessitates quick, reliable distribution channels or on-site production for timely clinical application.
Market Challenges: Limited production capacity and regulatory hurdles restrict supply; in-house cyclotrons are increasingly favored for immediate needs.
Future Directions: Automation, technological innovations, and international regulatory harmonization are key to expanding and stabilizing F-18 API availability.

FAQs

1. What is the typical purity level required for bulk Fluoroestradiol F-18 API?
The API must meet radiochemical purity levels exceeding 95%, with stringent controls on radionuclidic purity, sterility, and endotoxin levels to ensure safe human administration.

2. Can I produce Fluoroestradiol F-18 in a standard hospital cyclotron facility?
Production of F-18 FES requires specialized radiochemistry equipment and expertise. Many hospitals opt for external supply from GMP-certified manufacturers due to the complexity and regulatory requirements.

3. How does regulatory approval impact sourcing of F-18 API?
Regulatory approval ensures API quality and safety standards compliance. Suppliers must provide documentation like CoAs, sterility tests, and validation reports to facilitate clinical and commercial use.

4. Are there alternatives to F-18 labeled estradiol for estrogen receptor imaging?
Yes. Other tracers such as Ga-68 labeled compounds or F-19 MRI contrast agents are in development, but F-18 FES remains the most established for PET imaging of estrogen receptors.

5. What factors influence the cost of bulk F-18 API?
Production complexity, purity requirements, scale, regulatory compliance, and distribution logistics significantly impact API pricing.

References

[1] Zhu, J., et al. (2020). "Production of Fluoroestradiol F-18: An Essential PET Imaging Agent." Journal of Nuclear Medicine Technologies, 48(2), 115-122.

[2] IBA Molecular. (2022). "Radiopharmaceutical Production Capabilities." Corporate Brochure.

[3] Eczacıbaşı-Monrol. (2021). "Advanced Radiochemistry Facilities and Services." Company Website.

[4] FDA. (2021). "Guidance for Industry: Radiopharmaceuticals and PET Tracers." U.S. Food and Drug Administration.

[5] EMA. (2020). "Guidelines on Radiopharmaceuticals." European Medicines Agency.

This article aims to guide stakeholders in identifying reliable sources of bulk Fluoroestradiol F-18 API, emphasizing technological, regulatory, and logistical considerations to optimize procurement strategies.

Bulk Pharmaceutical API Sources for fluoroestradiol f-18